68Ga-NeoB与68Ga-PSMA-R2 PET/MRI在生化复发前列腺癌患者中的前瞻性比较
这项II期影像学研究前瞻性纳入27例初始治疗后疑似生化复发前列腺癌但常规影像无贡献的男性,在2周内分别行68Ga-NeoB与68Ga-PSMA-R2 PET/MRI。68Ga-NeoB检出18例(66.7%)共31个病灶,68Ga-PSMA-R2检出15例(55.6%)共20个病灶;68Ga-NeoB的灵敏度、准确率和阴性预测值更高,两者特异度和阳性预测值均为100.0%。两种显像剂均安全,但68Ga-PSMA-R2在肿瘤和背景器官中摄取均较低。
要点
- 68Ga-NeoB PET/MRI检出18例(66.7%)31个病灶,68Ga-PSMA-R2检出15例(55.6%)20个病灶。
- 68Ga-NeoB灵敏度85.7%、准确率88.9%、阴性预测值66.7%,均高于68Ga-PSMA-R2的71.4%、77.8%、50.0%。
- 两种显像剂特异度和阳性预测值均为100.0%,扫描前后生命体征无显著变化,72小时内无不良事件报告。
核心结论
- 68Ga-NeoB和68Ga-PSMA-R2用于诊断显像是安全的。
- 68Ga-NeoB PET/MRI的诊断效能优于68Ga-PSMA-R2。
- 68Ga-PSMA-R2在背景器官和肿瘤中摄取均较低,可能因此不是理想的诊疗一体化化合物。
- 需要在更大队列中进一步评估以确认这些初步数据。
研究设计与样本
- 这是一项II期影像学研究,前瞻性纳入27例初始治疗后疑似生化复发前列腺癌但常规影像(MRI、CT和/或骨扫描阴性或可疑)无贡献的男性。
- 参与者在2周内以非对照顺序接受68Ga-NeoB和68Ga-PSMA-R2 PET/MRI。
- 测量可疑前列腺癌病灶的SUVmax,并与复合参考标准(组织病理学、随访影像、前列腺特异性抗原变化)比较。
- 测量背景器官的SUVmax和SUVmean,注射放射性药物前和扫描后记录生命体征,每次扫描后72小时内记录不良事件。
主要发现
- 入组时前列腺特异性抗原水平为3.5 ± 3.9 ng/mL(范围0.3-13.5 ng/mL)。
- 68Ga-NeoB PET/MRI在18例患者(66.7%)中检出31个病灶,68Ga-PSMA-R2在15例参与者(55.6%)中检出20个病灶。
- 68Ga-NeoB PET/MRI的灵敏度为85.7%、准确率为88.9%、阴性预测值为66.7%,分别高于68Ga-PSMA-R2的71.4%、77.8%、50.0%;两者特异度和阳性预测值均为100.0%。
- 在6例患者中,68Ga-NeoB PET/MRI检出14个68Ga-PSMA-R2 PET/MRI假阴性的病灶。
- 病灶平均SUVmax为68Ga-NeoB 6.6 ± 3.2(范围2.9-13.2) vs 68Ga-PSMA-R2 4.4 ± 1.5(范围2.6-8.8),P = 0.019;68Ga-PSMA-R2在肿瘤和背景器官中摄取总体较低。
关键数值与推荐
- 68Ga-NeoB PET/MRI灵敏度85.7%、准确率88.9%、阴性预测值66.7%、特异度100.0%、阳性预测值100.0%。
- 68Ga-PSMA-R2 PET/MRI灵敏度71.4%、准确率77.8%、阴性预测值50.0%、特异度100.0%、阳性预测值100.0%。
- 病灶平均SUVmax:68Ga-NeoB 6.6 ± 3.2(范围2.9-13.2) vs 68Ga-PSMA-R2 4.4 ± 1.5(范围2.6-8.8),P = 0.019。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 需要在更大队列中进一步评估以确认这些初步数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors are both overexpressed in prostate cancer (PC) but may provide complementary information.68Ga-PSMA-R2 and 68Ga-NeoB (DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-NH-CH[CH2-CH(CH3)2]2) are novel PET radiopharmaceuticals that were developed for theranostic use. In this phase II imaging study, we assessed the feasibility, safety, and diagnostic performance of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI for detection of biochemically recurrent PC. Methods: We prospectively enrolled 27 men with suspected biochemically recurrent PC after initial treatment but noncontributory conventional imaging results (negative or equivocal findings on MRI, CT, and/or bone scan). Participants underwent 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI within 2 wk in noncontrolled order. The SUVmax of putative PC lesions was measured and compared with a composite reference standard (histopathology, follow-up imaging, prostate-specific antigen change). The SUVmax and SUVmean of background organs were measured. Vital signs were recorded before injection of the radiopharmaceuticals and after the scans. Adverse events were recorded up to 72 h after each scan. Results: The prostate-specific antigen level at enrollment was 3.5 ± 3.9 ng/mL (range, 0.3-13.5 ng/mL). 68Ga-NeoB PET/MRI detected 31 lesions in 18 patients (66.7%), whereas 68Ga-PSMA-R2 identified 20 lesions in 15 participants (55.6%). 68Ga-NeoB PET/MRI showed higher sensitivity (85.7% vs. 71.4%), accuracy (88.9% vs. 77.8%), and negative predictive value (66.7% vs. 50.0%) than 68Ga-PSMA-R2, whereas specificity and positive predictive value were equally high (100.0% for both). In 6 patients, 68Ga-NeoB PET/MRI identified 14 lesions that were false-negative on 68Ga-PSMA-R2 PET/MRI. The mean lesion SUVmax was 6.6 ± 3.2 (range, 2.9-13.2) for 68Ga-NeoB and 4.4 ± 1.5 (range, 2.6-8.8) for 68Ga-PSMA-R2 (P = 0.019). Overall lower uptake was noted in tumors and background organs for 68Ga-PSMA-R2. There were no significant changes in vital signs before and after the scans. No adverse events were reported in the 72-h period after scans. Conclusion: 68Ga-NeoB and 68Ga-PSMA-R2 are safe for diagnostic imaging. 68Ga-NeoB PET/MRI showed better diagnostic performance than 68Ga-PSMA-R2. 68Ga-PSMA-R2 showed overall lower uptake, equally in background organs and tumors, and might therefore not be an ideal theranostic compound. Further evaluation in larger cohorts is needed to confirm our preliminary data.
引用
- Duan H, Song H, Davidzon GA, et al. Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2024. PMID: 38664016. doi:10.2967/jnumed.123.267017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。